EQS-Adhoc: LR HEALTH & BEAUTY SE INITIATES A WRITTEN PROCEDURE UNDER ITS OUTSTANDING BOND LOAN IN RESPECT OF TEMPORARY WAIVERS AND SUPER SENIOR BRIDGE FINANCING

Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR HEALTH & BEAUTY SE INITIATES A WRITTEN PROCEDURE UNDER ITS OUTSTANDING BOND LOAN IN RESPECT OF TEMPORARY WAIVERS AND SUPER SENIOR BRIDGE FINANCING

Ahlen, 6 March 2026 – LR Health & Beauty SE (the “Company”) has, as of today, entered into further agreements with holders of the Company’s 2024/2028 bonds (ISIN: NO0013149658) (the “Bondholders” and the “Bonds”) representing more than two thirds (2/3) of the nominal amount of the Bonds (the “Majority Bondholders”) and the Company's shareholder regarding a comprehensive restructuring of the Bonds and the Company’s capital structure (the “Restructuring”).

A comprehensive restructuring, such as the Restructuring, will take time to implement which means that the Company will be in need of bridge financing in an amount of EUR 10,000,000 until the Restructuring is implemented. Certain Bondholders have undertaken to provide a bridge financing in the amount of EUR 10,000,000, having a super senior ranking in relation to the Bonds (the "Super Senior Bridge Financing"). The Super Senior Bridge Financing is intended to be refinanced in connection with closing of the Restructuring. Such Super Senior Bridge Financing may or may not share the security and guarantee package of the Bonds under an intercreditor agreement (in part or in full) and may further benefit from certain Super Senior Bridge Financing only share security.

In addition, the Majority Bondholders agreed to further extend the standstill undertaking comprising, inter alia, that Bondholders shall not derive any rights from breaches of the maintenance test (including the leverage covenant) or from any non-payments of interest until end of June 2026 (subject to extension).

In light of the above, the Company has today initiated a written procedure (the “Written Procedure”) under the Bonds to implement the above by way of amendments to and temporary waivers under the terms and conditions for the Bonds.

The notice of the Written Procedure and further details are accessible on the Company’s website at https://ir.lrworld.com/en/bond/.


IR contact:

cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de

2287320  06-March-2026 CET/CEST